Investor Relations

Corporate Overview

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures and CNS disorders for both hospital and home settings.

Read more

Why Invest


Years of combined rare disease experience


Patients safely treated using therapeutically relevant doses of ganaxolone


Treatment approved specifically for CDKL5 deficiency disorder

Latest News

View all news

Latest Presentation

Latest Events

View All Events